A Phase 2 interventional study of STAR-0215 in Hereditary Angioedema, sponsored by Astria Therapeutics, Inc.. Active, not recruiting at 22 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-23.
Sponsored by Astria Therapeutics, Inc. (part of BioCryst Pharmaceuticals) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Angioedemas, Hereditary by BioCryst Pharmaceuticals — 2 open to participants now, 5 under way, 4 of them phase 3. Angioedemas, Hereditary · BioCryst Pharmaceuticals.
Among the 22 studies in Angioedemas, Hereditary by BioCryst Pharmaceuticals, this one is the 10th largest by planned enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2023, is one of 4 in phase 2, and was the 20th registered.
171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.
Browse Angioedemas, Hereditary studies →2 of the 22 studies in Angioedemas, Hereditary by BioCryst Pharmaceuticals are open now, in 12 countries. Recruiting first, the newest first:
Astria Therapeutics, Inc. · Sites in United States, Brazil, Bulgaria and 15 more countries
Ages 12+
BioCryst Pharmaceuticals · Sites in Canada, Czechia, France and 8 more countries
Ages 2+
By country, each count listing its studies:
Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 7 · Phase 3 9
First in 2013; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 56 is above the median of 48 across 116 interventional studies indexed under Angioedemas, Hereditary.
Median enrollment 54 across the 21 interventional studies. Of the 16 that completed or were terminated, 7 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Astria Therapeutics, Inc., one of the names counted as BioCryst Pharmaceuticals. Under that name alone:
Astria Therapeutics, Inc. is the lead sponsor of 7 studies on the registry; 2 are open to participants now.
1 of the studies in Angioedemas, Hereditary by BioCryst Pharmaceuticals that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06842823Phase 3Astria Therapeutics, Inc.A Study of Navenibart in Participants With Hereditary Angioedema | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 22 studies in Angioedemas, Hereditary by BioCryst Pharmaceuticals, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this trial is to enable the collection of information about long-term safety and clinical activity of STAR-0215 in participants with hereditary angioedema (HAE). Participants will receive repeat doses of STAR-0215 for up to 5 years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Open to participants from STAR-0215-201 (NCT05695248) who have met one of the following conditions:
Exclusion Criteria:
Use of therapies prescribed for the prevention of HAE attacks prior to Screening:
Note: Other inclusion and exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive STAR-0215 every 3 months.
Drug: STAR-0215
Participants will receive STAR-0215 every 6 months.
Drug: STAR-0215
STAR-0215 will be administered as a subcutaneous injection.
Drug: STAR-0215
STAR-0215 will be administered as a subcutaneous injection.
Drug: STAR-0215
STAR-0215 will be administered as a subcutaneous injection.
Number of Participants Experiencing Treatment-emergent Adverse Events
Time frame: Day 1 through study completion, an average of 6 years
Change From Baseline in Monthly HAE Attack Rate
Time frame: Day 1, up to 5 years
Severity of HAE Attacks Experienced by Participants
All HAE attacks will be classified according to severity (mild, moderate, and severe).
Time frame: Day 1 through up to 5 years
Duration of HAE Attacks
Duration will be reported as shorter than 12 hours, 12 to 24 hours, 24 to 48 hours, and longer than 48 hours.
Time frame: Day 1 through up to 5 years
Number of Participants Experiencing HAE Attacks Requiring On-demand Therapy
Time frame: Day 1 through up to 5 years
Time to First HAE Attack After Each Dose
Time frame: Day 1 through up to 5 years
Number of HAE Attack-free Days
Time frame: Day 1 through up to 5 years
Number of Participants Experiencing Zero HAE Attacks
Time frame: Day 1 through up to 5 years
Serum Concentration of STAR-0215
Blood samples will be collected on dosing days to measure the serum concentration of STAR-0215.
Time frame: Every 3 months for first 2 years, Every 6 months for next 3 years
Plasma Levels of Cleaved High-molecular-weight Kininogen
Blood samples will be collected on dosing days to measure the plasma levels of cleaved high-molecular-weight kininogen (a measure of plasma kallikrein activity).
Time frame: Every 3 months for first 2 years, Every 6 months for next 3 years
Number of Participants with Anti-drug Antibodies to STAR-0215
Blood samples will be collected on dosing days to assess the formation of STAR-0215 anti-drug antibodies in serum.
Time frame: Every 3 months for first 2 years, Every 6 months for next 3 years
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2023 (actual). Primary completion is estimated for Mar 2031, 90 months after the start.
Of 17 phase 2 interventional studies under Angioedemas, Hereditary, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 35. This study's planned 90 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Navenibart